 |
|
Patients who wake up with stroke may be candidates for clot-busters
March 13, 2009Giving clot-busting drugs to patients who wake up with stroke symptoms appears to be as safe as giving it to those in the recommended three-hour window, according to researchers at The University of Texas Medical School at Houston.
The results of the study, "Thrombolytic Therapy for Patients Who Wake Up With Stroke," are published in the March issue of Stroke, a journal of the American Heart Association.
"The results of our study serve as the only published material of patients who woke up with ischemic stroke symptoms and were treated with thrombolytic therapy," said Andrew Barreto, M.D., lead author and assistant professor of neurology at the UT Medical School at Houston. "It stands as the only support for the safety of stroke treatment in wake-up stroke patients."
Stroke occurs when blood flow to the brain is interrupted by a blockage or a rupture in an artery, depriving brain tissue of oxygen. It is the third-leading cause of death behind heart disease and cancer. According to the American Stroke Association, nearly 800,000 Americans suffer a stroke each year - one every 40 seconds. On average, someone dies of stroke every three to four minutes.
According to protocol from the U.S. Food and Drug Administration, thrombolytic medications such as intravenous tissue plasminogen activator (tPA) should be given to patients with a blockage within three hours of the onset of stroke symptoms.
Approximately 25 percent of patients with a blockage, called an ischemic stroke, wake up with their symptoms. That could place them outside the three-hour window and therefore they are not normally given tPA, except under an off-label, compassionate care exemption.
"The offer of compassionate tPA treatment was made by the treating stroke neurologist," Barreto said. "Usually these were younger patients with moderate to severe disabling strokes who had no other treatment options."
The researchers compared 174 patients who were treated with tPA within the three-hour, standard-of-care window with 46 wake-up stroke patients who received off-label thrombolytic therapy. The two groups experienced similar rates of excellent outcomes and favorable outcomes.
In addition, wake-up stroke patients treated with thrombolytic therapy have higher rates of excellent and favorable outcomes than wake-up stroke patients who did not receive it, according to the research.
Barreto said further studies will need to occur to verify the results.
"An indication for treatment of thrombolytic therapy will only come after large, randomized, blinded/controlled clinical trials are conducted," he said. Barreto and senior author Sean Savitz, M.D., assistant professor of neurology at the medical school, are currently working with other stroke centers to create collaboration and set up such a trial.
University of Texas Health Science Center at Houston
Stroke occurs when blood flow to the brain is interrupted by a blockage or a rupture in an artery, depriving brain tissue of oxygen. It is the third-leading cause of death behind heart disease and cancer. According to the American Stroke Association, nearly 800,000 Americans suffer a stroke each year - one every 40 seconds. On average, someone dies of stroke every three to four minutes.
According to protocol from the U.S. Food and Drug Administration, thrombolytic medications such as intravenous tissue plasminogen activator (tPA) should be given to patients with a blockage within three hours of the onset of stroke symptoms.
Approximately 25 percent of patients with a blockage, called an ischemic stroke, wake up with their symptoms. That could place them outside the three-hour window and therefore they are not normally given tPA, except under an off-label, compassionate care exemption.
"The offer of compassionate tPA treatment was made by the treating stroke neurologist," Barreto said. "Usually these were younger patients with moderate to severe disabling strokes who had no other treatment options."
The researchers compared 174 patients who were treated with tPA within the three-hour, standard-of-care window with 46 wake-up stroke patients who received off-label thrombolytic therapy. The two groups experienced similar rates of excellent outcomes and favorable outcomes.
In addition, wake-up stroke patients treated with thrombolytic therapy have higher rates of excellent and favorable outcomes than wake-up stroke patients who did not receive it, according to the research.
Barreto said further studies will need to occur to verify the results.
"An indication for treatment of thrombolytic therapy will only come after large, randomized, blinded/controlled clinical trials are conducted," he said. Barreto and senior author Sean Savitz, M.D., assistant professor of neurology at the medical school, are currently working with other stroke centers to create collaboration and set up such a trial.
University of Texas Health Science Center at Houston
Thrombolytic Current Events and Thrombolytic News RSSStanford study recommends change in treating pulmonary embolisms
William Kuo, MD, was the on-call interventional radiologist one Friday night three years ago when he received a call from the intensive care unit at Stanford Hospital & Clinics.
Aspirin and similar drugs may be associated with brain microbleeds in older adults
Individuals who take aspirin or other medications that prevent blood clotting by inhibiting the accumulation of platelets appear more likely to have tiny, asymptomatic areas of bleeding in the brain.
Rush University Medical Center Orthopedic Experts Examine Overhead Throwing Injuries
Baseball season is underway. With the pros, college and high school teams taking to the baseball diamonds and Little Leaguers soon to follow, orthopedic specialists at Rush University Medical Center are cautioning players to be aware of and take precautions against throwing injuries.
Stroke therapy window might be extended past nine hours for some
Some patients who suffer a stroke as a result of a blockage in an artery in the brain may benefit from a clot-busting drug nine or more hours after the onset of symptoms. The findings are published in the online edition of Radiology.
Portable CT increases chance of stroke survival and recovery
New research has found that the availability of a portable eight-slice computed tomography (CT) scanner in an emergency room can significantly increase the number of stroke victims who receive a potentially life-saving treatment.
WVU study demonstrates efficacy of CT perfusion in diagnosis of acute ischemic stroke
A study conducted by a team of stroke experts from West Virginia University Health Sciences Center demonstrates that CT (computed tomography) perfusion imaging - a technology which measures blood flow and is available to most hospitals - may dramatically improve fast and accurate stroke diagnosis, enabling physicians to provide more targeted care and helping avoid potentially life-threatening complications of "clot buster" therapy.
New research could save lives and millions of dollars
The Hunter Medical Research Institute (HMRI) Stroke Research Group has developed a system to fast track stroke treatment which could benefit thousands of Australian stroke patients and save millions of dollars annually.
Treatment window expanded
Patients can still benefit up to 4.5 hours after a stroke if a drug that dis-solves blood clots in the brain is administered. Thus far, three hours had been considered the useful limit for administering thrombolytic drugs.
New blood clot guidelines for pregnant women
New evidence-based guidelines address the prevention and management of thrombosis in key patient populations and reinforce recommendations related to the routine use of preventive therapies.
Avoiding Spleen Removal for Cooley's Anemia Sufferers
Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in one of the world's most common blood disorders, beta-thalassemia, commonly known as Cooley's anemia.
More Thrombolytic Current Events and Thrombolytic News Articles
|
Guidelines for thrombolytics need updating.(Cardiovascular Medicine): An article from: Internal Medicine News by Christine Kilgore (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on January 15, 2005. The length of the article is 864 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Guidelines for thrombolytics need updating.(Cardiovascular Medicine) Author: Christine Kilgore Publication: Internal Medicine News (Magazine/Journal) Date: January 15, 2005 Publisher: International Medical News Group Volume: 38 Issue: 2 Page: 62(1) Distributed by Thomson... | |
 |
Nattokinase Plus (100 mg, 90 capsules) by Vesta Pharmaceuticals In the 1980s, Dr. Hiroyuki Sumi at the University of Chicago isolated the circulation-promoting enzyme in natto and called it Nattokinase, meaning enzyme from natto. Research (including two small human trials) has shown Nattokinase supports healthy blood flow by assisting in the circulatory clearing system of the body. Specifically, Nattokinase supports the fibrinolytic clearing system in the body which is responsible for healthy circulation, by helping to break down fibrin protein deposits in the bloodstream to promote and enhance healthy blood flow. |
|
Chest. Antithrombotic and Thrombolytic Therapy. (Official Publication of the American College of Chest Physicians): Volume 133, Number 6, June 2008. Supplement to Chest. 8th Edition by Richard S. Irwin (Author) | |
|
Thrombolytic Therapy in the Treatment of Mi [VHS] Starring: Health and Sciences Television Network | |
 |
Thrombolytic Therapy for Stroke by Patrick D. Lyden (Editor) UCSD Stroke Center, San Diego, CA. A text for clinicians treating patients in the first few hours after a stroke, providing all of the data necessary to understand the limitations of thrombolytic therapy. Includes protocols and case tutorials introducing the indications and contraindications of this type of therapy. DNLM: Cerebrovascular Accident--drug therapy. |
|
Thrombolytic Therapy for Peripheral Vascular Disease (Books) by Anthony J. Comerota (Editor) This comprehensive text is liberally illustrated to assist the clinician in properly identifying and treating patients requiring thrombolytic therapy. Authoritatively written, this practical text addresses modern therapies for deep acute venous thrombosis, primary and secondary axillo-subclavian vein thrombosis, acute limb ischemia, chronic arterial occlusion, and occluded access grafts. It also covers a complete range of lytic agents including streptokinase, urokinase, acylated streptokinase, prourokinase, recombinant tissue plasminogen activator and a new kinase for preventing strokes. | |
|
Review of Thrombolytic Therapy and Thromboembolic Disease by William R. Bell (Editor), Arthur A. Sasahara (Editor), Tim Phelps (Editor) | |
|
Proceedings of the Conference on Thrombolytic Agents (April 8-9, 1960) by Harold R. Roberts (Editor), J. Dieter Geratz (Editor) Proceedings of the conference held April 8-9, 1960, in Chicago, Illinois. Sponsored by the Hematology Study Section, Public Health Service. | |
|
Thrombolytic Therapy In Acute Ischemic S by Takenori Yamaguchi (Author) | |
|
Thrombolytic Therapy in Acute Ischemic Stroke II by Gregory J. Del Zoppo (Author), Etsuro Mori (Author), Werner Hacke (Editor) |
| © 2009 BrightSurf.com |